Evidence map›Paper›PMID 32340991›Full record

ArticleAntimicrobial agents and chemotherapy2020

Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery.

Rana Abdelnabi, Kristina Kovacikova, Julia Moesslacher, Kim Donckers, Verena Battisti, Pieter Leyssen, Thierry Langer, Gerhard Puerstinger, Gilles Quérat, Changqing Li and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Nervous System Manifestations of Arboviral Infections.Current tropical medicine reports · 2022
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rana Abdelnabi *KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Kristina Kovacikova *Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands.
Julia MoesslacherDepartment of Pharmaceutical Chemistry, University of Innsbruck, Innsbruck, Austria.
Kim DonckersKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Verena BattistiUniversity of Vienna, Department of Pharmaceutical Chemistry, Vienna, Austria.
Pieter LeyssenKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Thierry LangerUniversity of Vienna, Department of Pharmaceutical Chemistry, Vienna, Austria.
Gerhard PuerstingerDepartment of Pharmaceutical Chemistry, University of Innsbruck, Innsbruck, Austria.
Gilles QuératUnité des Virus Emergents (UVE: Aix-Marseille University-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France.
Changqing LiAix Marseille University, CNRS, AFMB UMR7257, Marseille, France.
Etienne DecrolyAix Marseille University, CNRS, AFMB UMR7257, Marseille, France.
Ali TasMolecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands.
Arnaud MarchandCentre for Drug Design and Discovery, KU Leuven, Leuven, Belgium.
Patrick ChaltinCentre for Drug Design and Discovery, KU Leuven, Leuven, Belgium.
Bruno CoutardUnité des Virus Emergents (UVE: Aix-Marseille University-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France.
Martijn van HemertMolecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands.
Johan Neyts *KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
Leen Delang *KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium Leen.Delang@kuleuven.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the worldwide reemergence of the chikungunya virus (CHIKV) and the high morbidity associated with CHIKV infections, there is no approved vaccine or antiviral treatment available. Here, we aimed to identify the target of a novel class of CHIKV inhibitors, i.e., the CHVB series. CHVB compounds inhibit the

Indexed as

Chikungunya FeverChikungunya virusAnimalsAntiviral AgentsChlorocebus aethiopsVero CellsViral Nonstructural ProteinsVirus ReplicationAntiviral AgentsViral Nonstructural Proteinsantiviralscappingchikungunya virusCHIKVMADTPnonstructural protein 1nsP1

Identifiers

PMID32340991
PMCPMC7317993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.